LTI
2.8.2022 11:02:08 CEST | Business Wire | Press release
Larsen & Toubro Infotech (BSE: 540005, NSE: LTI ), a global technology consulting and digital solutions company, has announced the expansion of its collaboration with Microsoft to focus on developing high-value cloud solutions for enterprises. As a part of this multi-year collaboration, LTI has launched a dedicated Microsoft business unit that develops and offers end-to-end digital transformation solutions.
Through this association, LTI will also train 12,000 professionals from its existing workforce on various Microsoft technologies by 2024. The main objective of this effort is to enable skill development of LTI employees that are a part of the Microsoft unit and enhance their competencies across technologies like cloud, data, IoT and security.
Nachiket Deshpande, Chief Operating Officer, LTI, said, “LTI has a long-standing relationship with Microsoft as a strategic partner, service provider, and customer. Our reaffirmed partnership with Microsoft will enable us to innovate and offer 170+ distinct services to our joint customers. Additionally, we will also focus on the training and upskilling of our talent pool that is a part of the dedicated Microsoft business unit, to empower them to meet changing business and market requirements.”
Siddharth Bohra, Chief Business Officer & Head of Cloud Business Unit, LTI , said, “Enterprises across the globe are increasingly embracing cloud, and LTI has made impressive strides in developing a multi-dimensional capability on Azure to meet this demand. As part of this collaboration, LTI and Microsoft will jointly innovate, develop, and sell solutions to assist enterprises in acceleration of their digital transformation journeys.”
Julie Sanford, Vice President, Partner GTM, Programs & Experiences, Microsoft , said, “Through their new Microsoft Business Unit, LTI will be able to help customers implement cloud strategies and drive business transformation across industries and geographies. We look forward to working with LTI as they build new capabilities and deliver innovative solutions on the Microsoft Cloud.”
Through this association, LTI will attain the Solution Partner designation across all the Microsoft Solution Areas. LTI also has the following advanced specializations on Azure:
- SAP on Azure : Validating the capability of implementing SAP solutions on Azure.
- Analytics on Azure : Demonstrating the expertise in delivering analytics solutions in Microsoft Azure.
- Windows Server and SQL Server : Expertise in migrating production workloads to Microsoft Azure.
- Modernization of Web Applications : Validating expertise in migrating and deploying production web application workloads, applying DevOps, and managing app services in Microsoft Azure.
- Kubernetes on Azure : validating capabilities in deploying and managing production workloads in the cloud using containers and managing hosted Kubernetes environments in Azure.
- Low Code Application Development : Expertise in building solutions using Power Apps.
- The Data Warehouse Migration to Microsoft Azure : Validating expertise in analyzing existing workloads and performing ETL operations to migrate data to cloud-based data warehouses.
- Cloud Security : Validates a means for your company to showcase capabilities to implement comprehensive security solutions across Azure, hybrid, and multi-cloud environments.
- Threat Protection : provides a means for your company to showcase proven, verifiable expertise in deploying Microsoft Threat Protection or Microsoft Cloud App Security workloads.
- AI and Machine Learning in Microsoft Azure : Validates capabilities on enabling customer adoption of Al and implementing Azure solutions for Al-powered apps.
LTI is an Azure Expert MSP Partner which demonstrates deep knowledge, extensive experience, and proven success in implementing specialized workloads such as Migration and Modernization, SAP on Azure, Data Analytics, Internet of things (IoT), Security, and Microsoft Dynamics 365.
About LTI:
LTI (NSE: LTI ) is a global technology consulting and digital solutions Company helping more than 495 clients succeed in a converging world. With operations in 33 countries, we go the extra mile for our clients and accelerate their digital transformation journeys. Founded in 1997 as a subsidiary of Larsen & Toubro Limited, our unique heritage gives us unrivalled real-world expertise to solve the most complex challenges of enterprises across all industries. Each day, our team of more than 46,000 LTItes enable our clients to improve the effectiveness of their business and technology operations and deliver value to their customers, employees, and shareholders. Find more at https://www.lntinfotech.com or follow us at @LTI_Global .
Connect with LTI:
Read More:
- LTI Becomes Microsoft Azure Expert Managed Services Provider
- LTI has Earned the Kubernetes on Microsoft Azure Advanced Specialization
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005516/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom